Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e445-e447. doi: 10.1016/j.clml.2018.06.020. Epub 2018 Jun 27.

Authors

Francine M Foss¹, Terri L Parker², Michael Girardi³, Anlong Li⁴

Affiliations

¹ Department of Hematology, Yale University School of Medicine, New Haven, CT. Electronic address: [email protected].
² Department of Hematology, Yale University School of Medicine, New Haven, CT.
³ Department of Dermatology, Yale University School of Medicine, New Haven, CT.
⁴ Yale University School of Medicine, New Haven, CT.

PMID: 30181105
DOI: 10.1016/j.clml.2018.06.020

No abstract available

Keywords: Leucovorin; Lymphoma; Mucositis; Pralatrexate; Therapy.

MeSH terms

Aminopterin / analogs & derivatives*
Aminopterin / therapeutic use
Dose-Response Relationship, Drug
Female
Folic Acid Antagonists / therapeutic use*
Follow-Up Studies
Humans
Lymphoma, T-Cell, Cutaneous / drug therapy*
Lymphoma, T-Cell, Cutaneous / pathology
Male
Middle Aged
Prognosis
Retrospective Studies
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

10-propargyl-10-deazaaminopterin
Folic Acid Antagonists
Aminopterin